Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

Summary

Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients. Vitamin D use in dialysis patients has been shown to have a survival benefit, with paricalcitol at advantage over calcitriol. Since there is some evidence for involvement of the vitamin D receptor in inflammation, this study is designed to look for an effect of paricalcitol on markers of inflammation in hemodialysis patients.

Timeline

Start

2006-03

Primary completion

2008-01

Completion

2008-01

Drugs

Indications